Navigation Links
Joseph B. Bolen, Ph.D. from Millennium to Conference Chair Cancer Sessions at IBC's Drug Discovery & Development of Innovative Therapeutics Conference
Date:6/30/2008

WESTBOROUGH, Mass. June 30 /PRNewswire/ -- Joseph B. Bolen, Ph.D., CSO of Millennium Pharmaceuticals, will chair the Focus on Cancer track IBC Life Sciences Drug Discovery & Development of Innovative Therapeutics Conference and Exhibition taking place August 4-7 at the World Trade Center Boston & Seaport Hotel in Boston, MA. The cancer track presentations will focus on therapies for Hematology, Lung Cancer, Blood Borne Cancers, and Clinical Biomarkers.

Bolen has confirmed academia speakers including: Kenneth C. Anderson, M.D., Dana Farber Cancer Institute, Harvard Medical School; Bruce E. Johnson, M.D., Dana-Farber Cancer Institute, Harvard Medical School, Brigham and Women's Hospital; Mark A. Israel, M.D., Dartmouth Medical School; Neal Rosen, M.D., Ph.D., Memorial Sloan-Kettering Cancer Center; Massimo Loda, M.D., Dana Farber Cancer Institute, Brigham & Women's Hospital, Harvard Medical School

Companies also giving technical conference presentations in this cancer track include Alnylam Pharmaceuticals, Amgen, Inc., ARIAD Pharmaceuticals Inc., ArQule, Inc., AstraZeneca R&D Boston, Bristol-Myers Squibb Company, Exelixis Inc, Genzyme Corporation, Infinity Pharmaceuticals, Inc, Merck Research Laboratories, Novartis Institutes for BioMedical Research, OncoMed Pharmaceuticals Inc, The Johnson & Johnson Family of Companies.

Additional conference sessions at Drug Discovery & Development of Innovative Therapeutics conference include:

-- Cardio-Metabolic Disease Drug Discovery and Development

-- Translational Medicine/Research

-- Transforming Technologies

-- Anti-Infective Drug Discovery and Development

-- Neurodegenerative Disease Drug Discovery and Development

-- Inflammation in Drug Discovery and Development

-- Orphan Diseases: Fast-Tracking Orphan Drugs and Scientific Advances -- The Next Generation of Therapeutics: Emerging Biologics, Stem Cells and RNAi

IBC's Drug Discovery & Development of Innovative Therapeutics Conference and Exhibition is an international event that covers topics across multiple therapeutic areas. The event includes over 15 presentations from more than 200 speakers, 150 exhibitors, 13 interactive round table discussions and 4 keynote presentations. For more information please visit http://www.drugdisc.com.

Complete details on this event can be found at http://www.drugdisc.com or to receive a press pass or arrange an interview with a speaker, email Keri Dostie at kdostie@ibcusa.com.

About IBC Life Sciences

IBC Life Sciences is the worldwide leader in scientific, technological and business conferences and courses for the life science industry. To develop its programs, IBC actively researches the advancements, technologies and trends impacting and driving the race for new drugs and therapies. No other organization can make claim to the breadth and quality that IBC Life Sciences delivers in each event giving the company recognition around the globe for quality, service and value. For more information, visit: http://www.IBCLifeSciences.com.

Contact: Keri Dostie

IBC Life Sciences

508-614-1404

kdostie@ibcusa.com


'/>"/>
SOURCE IBC Life Sciences
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Seahorse Bioscience Appoints Former Molecular Devices Executive Dr. Joseph D. Keegan to Board of Directors
2. Dr. Joseph L. Corriveau Appointed Director of Research and Technology
3. SGX Pharmaceuticals Appoints Joseph L. Turner to Board of Directors
4. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
5. J. Craig Venter Institute Names Robert Friedman, Ph.D., Deputy Director of West Coast Facility
6. Barry Ginsberg, M.D., Ph.D. Elected to Biodels Board of Directors
7. DermTech Names Herbert A. Fritsche, Ph.D., Chief of Clinical Chemistry at M.D. Anderson Cancer Center to Companys Scientific Advisory Board
8. Takedas Antibody Therapeutics Research Company, Takeda San Francisco, Inc. Appoints Mary Haak-Frendscho, Ph.D. as President and CSO
9. Lucy Shapiro, Ph.D., Elected to Gen-Probe Board of Directors
10. Adnavance Technologies Inc. Appoints Christian P. Valcke, Ph.D., to Its Scientific Advisory Board
11. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
Breaking Biology Technology:
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of the medical ... premium product recently added to the range of products distributed by Ampronix. ... ... ... Ampronix News ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... , April 28, 2016 Infosys ... (NYSE: INFY ), and Samsung SDS, a global ... that will provide end customers with a more secure, fast ...      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... but it also plays a fundamental part in enabling and ...
Breaking Biology News(10 mins):